Tevogen Bio Holdings Faces Delisting Notice

TL;DR

Tevogen Bio Holdings got a delisting warning, might be in trouble.

AI Summary

Tevogen Bio Holdings Inc. filed an 8-K on September 23, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Semper Paratus Acquisition Corp, is incorporated in Delaware and its principal executive offices are located in Warren, NJ.

Why It Matters

This filing indicates potential issues with Tevogen Bio Holdings' continued listing on an exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.

Key Players & Entities

• Tevogen Bio Holdings Inc. (company) — Registrant
• Semper Paratus Acquisition Corp (company) — Former company name
• September 23, 2025 (date) — Date of earliest event reported
• Warren, NJ (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share TVGN The Nasdaq Stock Mar
• $11.50 — sable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Ma
• $1.00 — at the Company no longer meets Nasdaq's $1.00 per share minimum bid price requirement

Filing Documents

• form8-k.htm (8-K) — 43KB
• 0001493152-25-015784.txt ( ) — 255KB
• tvgn-20250923.xsd (EX-101.SCH) — 4KB
• tvgn-20250923_def.xml (EX-101.DEF) — 26KB
• tvgn-20250923_lab.xml (EX-101.LAB) — 37KB
• tvgn-20250923_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2025 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-41002 98-1597194 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 15 Independence Boulevard , Suite #210 Warren , New Jersey 07059 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: ( 877 ) 838-6436 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share TVGN The Nasdaq Stock Market LLC Warrants, each exercisable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 23, 2025, Tevogen Bio Holdings Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company no longer meets Nasdaq's $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Requirement") for continued listing on Nasdaq based on the closing bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), for the previous 30 consecutive business days. The notification received has no immediate effect on the Company's listing or trading on the Nasdaq Global Market. The Company has been provided a period of 180 calendar days, or until March 23, 2026 (the "Compliance Date"), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Common Stock closes at $1.00 or more for a minimum of 10 consecutive business days and up to generally not more than 20 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company will be required to transfer to the Nasdaq Capital Market and meet the continued listing requirement for market value of its publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second 180 calendar day compliance period. The Company intends to actively monitor the closing bid price of the Common Stock in addition to its ongoing monitoring of the market integrity of the Common Stock. The Company may evaluate and consider available options to regain compliance with the Bid Price Requirement. However, there can be no assurance that the Company will take any specific action or otherwise be able to regain compliance with the Bid Price Requirement or otherwise maintain compliance with Nasdaq listing rules. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Tevogen Bio Holdings Inc. Date: September 26, 2025 By: /s/ Ryan Saadi Name: Ryan Saadi Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR